{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=11",
    "query": {
      "condition": "Neuroectodermal Tumor",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 5012,
    "total_pages": 502,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T21:14:20.793Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00582608",
      "title": "Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "CNS Cancer",
        "Neuroblastoma",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "131I-8H9",
          "type": "DRUG"
        },
        {
          "name": "8H9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "1 Year to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2001-10",
      "completion_date": "2009-05",
      "has_results": true,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582608"
    },
    {
      "nct_id": "NCT00135876",
      "title": "Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Brain Tumors"
      ],
      "interventions": [
        {
          "name": "dalteparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ontario Clinical Oncology Group (OCOG)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2002-10",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2007-04-27",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 3,
      "location_summary": "Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135876"
    },
    {
      "nct_id": "NCT02052648",
      "title": "Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioma",
        "Gliosarcoma",
        "Malignant Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Indoximod",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Radiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NewLink Genetics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2014-03",
      "completion_date": "2019-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-03-27",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 17,
      "location_summary": "Castro Valley, California • Los Angeles, California • Orange, California + 14 more",
      "locations": [
        {
          "city": "Castro Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052648"
    },
    {
      "nct_id": "NCT00001685",
      "title": "Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 114,
      "start_date": "1997-11",
      "completion_date": "2000-09",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001685"
    },
    {
      "nct_id": "NCT00002515",
      "title": "Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Germ Cell Tumor",
        "Extragonadal Germ Cell Tumor",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Liver Cancer",
        "Lymphoma",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Retinoblastoma",
        "Sarcoma",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "autologous bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1992-10",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002515"
    },
    {
      "nct_id": "NCT01505608",
      "title": "Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "TPI 287",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Giselle Sholler",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 14,
      "start_date": "2011-12",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2024-08-06",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • San Diego, California • Hartford, Connecticut + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01505608"
    },
    {
      "nct_id": "NCT06831552",
      "title": "Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroblastoma",
        "High-risk Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "RISE Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 84,
      "start_date": "2025-04-30",
      "completion_date": "2029-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 6,
      "location_summary": "Hartford, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06831552"
    },
    {
      "nct_id": "NCT02159443",
      "title": "Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ewing Family of Tumors",
        "Melanoma",
        "Neuroblastoma",
        "Osteosarcoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 76,
      "start_date": "2014-07-15",
      "completion_date": "2020-04-24",
      "has_results": false,
      "last_update_posted_date": "2020-11-05",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02159443"
    },
    {
      "nct_id": "NCT04244552",
      "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Ovarian Cancer",
        "Non-Small Cell Lung Cancer",
        "Acral Lentiginous Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Hepatocellular Carcinoma",
        "Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "DMMR Colorectal Cancer",
        "MSI-H Colorectal Cancer",
        "Melanoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ATRC-101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated liposomal doxorubicin (PLD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Atreca, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2020-02-11",
      "completion_date": "2023-11-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244552"
    },
    {
      "nct_id": "NCT00070343",
      "title": "Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "oblimersen sodium",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2003-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-01-06",
      "last_synced_at": "2026-10-22T21:14:20.793Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00070343"
    }
  ]
}